🟢 Edesa Biotech is trading 5% up today in pre-market after fiscal third-quarter report and EB06 site activation

Edesa Biotech is trading 5.16% up at $5.71 after its August 13, 2026 fiscal third-quarter report and EB06 trial progress.

• Reported a $5.4 million net loss, or $0.60 per share, alongside an earnings miss and widening loss.
• Confirmed Phase 2 EB06 vitiligo-study preparations and investigational-site activation, with recruitment upcoming.
• No reliable volume or additional August 14 company-specific announcement was identified; broader futures were modestly positive, but the earnings release remains the clearest catalyst.